Eletriptan

CNS Drugs

Volumn 12, Issue 4, 1999, Pages 325-333

  Bardsley Elliot, Anne ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ELETRIPTAN; SUMATRIPTAN;

ASTHENIA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; MIGRAINE; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VERTIGO;

EID: 0032696211     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912040-00006     Document Type: Review

References (38)

1. Hamel E, Fan E, Linville D, et al. Expression of mRNA for the serotonin 5-hydroxytryptamine ID beta receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 1993 Aug; 44 (2); 242-6
2. Bouchelet I, Cohen Z, Case B, et al. Differential expression of sumatriptan-sensitive 5-hydroxytriptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996 Aug: 50 (2); 219-23
3. 1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997; 17: 833-42
4. Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. Drugs 1998 Jun; 55: 889-922
5. 1D-like receptor partial agonist [abstract). Headache 1997 May; 37: 311-2
6. 1D receptors. Eur J Pharmacol 1999; 368: 259-68
7. Johnson KW, Schaus JM, Durkin MM, et al. 5-HTIF receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997 Jul 7; 8 (9-10): 2237-40
8. Wallis R, Gupta P. Napier CM, et al. Understanding the pharmacology of eletriptan [abstract]. Headache 1997 May; 37: 335
9. 1B receptor. Eur J Pharmacol 1999; 367: 283-90
10. 1Dlike receptor [abstract]. Cephalagia 1996 Aug; 16: 386
11. 1B/1D receptor agonist with anti-migraine activity. Naunyn Schmiedebergs Arch Pharmacol 1998 Aug; 358: 212-9
12. Maassen VanDenBrink A, van den Broek RWM, de Vries R, et al. Human middle meningeal and coronary artery contraction to eletriptan and sumatriptan [abstract]. Cephalalgia 1999 May; 19 (4): 398
13. van den Broek RWM, Maassen VanDenBrinK A, Avezaat CJJ, et al. Pharmacological analysis of eletriptan-induced contraction in the human isolated middle meningeal artery [abstract]. Cephalalgia 1999 May; 19 (4): 398-9
14. Data on file, Pfizer Limited, 1999
15. Rance DJ, Horspool K, James G, et al. The absorption potential of eletriptan (UK-116,044) and sumatriptan [abstract). Cephalalgia 1996 Aug; 16: 387
16. 1D-like' receptor agonist [abstract]. Cephalalgia 1996 Aug; 16: 385
17. 1D-like' receptor agonist [abstract]. Cephalalgia 1996 Aug; 16: 368
18. 1d-like' receptor partial agonist [abstract]. Headache 1997 May; 37: 324
19. Johnson BF, Shah A, Law G. The absorption kinetics of eletriptan in migraineurs [abstract]. Cephalalgia 1997 May; 17: 415
20. Shah AK, Laboy-Goral L, Morse TA, et al. The pharmacokinetics of oral eletriptan, and its excretion into breast milk in normal, healthy, nursing women [abstract], Cephalalgia 1998 Jul-Aug; 18: 412
21. Morgan P, Rance DJ, James G, et al. An in vitro-in vivo correlation of eletriptan pharmacokinetics and metabolism in rat, dog, and human [abstract]. Headache 1997 May; 37: 324
22. Hyland R, Jones BC, McCleverty P, et al. In vitro metabolism of eletriptan in human liver microsomes [abstract]. Cephalalgia 1998 Jul-Aug; 18; 404
23. Milton KA, Buchanan TJ, Haug-Pihale G, et al. The pharmacokinetics, safety, and tolerability of oral eletriptan in subjects with impaired hepatic function [abstract]. Cephalalgia 1998 Jul-Aug; 18: 411-2
24. Milton KA, Tan E, Boyce MJ, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of oral eletriptan in young and elderly, male und female subjects [abstract]. Cephalalgia 1998 Jul-Aug; 18: 405
25. Milton KA, Tan L, Love R. The pharmacokinetic and pharmacodynamic interactions of oral eletriptan and propranolol in healthy volunteers [abstract]. Cephalalgia 1998 Jul-Aug; 18: 412
26. Steiner TJ. Eletriptan Steering Committee, et al. Efficacy, safety, and tolerability of oral eletriptan (40 mg and 80 mg) in the acute treatment of migraine: results of a phase III study [abstract]. Cephalalgia 1998 Jul-Aug; 18: 385
27. Stark R, Eletriptan Steering Committee. The efficacy, safety and tolerability of oral eletriptan (40 mg and 80 mg) for the acute treatment of migraine [abstract]. Eur J Neurol 1998; 5 Suppl. 3: S57
28. Dowson A, Eletriptan Steering Committee. Evaluating eletriptan for the acute treatment of migraine [abstract]. 3rd EFNS Migraine; 1998 Sep 21: 4
29. Pitman V. Headache recurrence following single doses of oral eletriptan: review of clinical trial experience [abstract]. Cephalalgia 1999 May; 19(4): 354
30. Poole PH, Haughie SR. Treatment of headache recurrence with a second dose of oral eletriptan: meta analysis across phase III clinical trials [abstract]. Cephalalgia 1999 May; 19 (4): 354-5
31. Wells N. Migraine treatment: regaining lost time; new eletriptan study results [abstract]. 4th European Headache Federation Congress; 1998 Jun 12-16; Corfu
32. Wells N. Migraine treatment: regaining lost time. New eletriptan study [poster 98/5431]. 1999 Meeting of the American Association for the Study of Headache (AASH); Jan 22-24; San Juan, Puerto Rico
33. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: results of a double-blind, placebo-controlled comparison to sumatriptan. Neurology 1999. In press
34. Pryse-Phillips W, Eletriptan Steering Committee. Comparison of oral eletriptan (40-80 mg) and oral sumatriptan (50-100 mg) for the treatment of acme migraine; a randomised, placebo-controlled trial in sumatriptan-naive patients [abstract]. Cephalalgia 1999 May; 19 (4): 355
35. Wells N. Comparison of the effectiveness of oral eletriptan (4080 mg) and oral sumatriptan (50-100 mg) in reducing the time loss and overall impact of migraine attacks [abstract]. Cephalalgia 1999 May; 19 (4): 354
36. Reches A, Eletriptan Steering Committee. Comparison of the efficacy, safety and tolerability of oral eletriptan and Cafergot for the acute treatment of migraine [abstract]. Cephalalgia 1999 May; 19 (4): 355
37. Färkkilä M. A dose-finding study of eletriptan (UK-116,044) (5-30 mg) for the acute treatment of migraine [abstract). Cephalalgia 1996 Aug; 16: 387-9
38. Poole PH, Eletriptan Steering Committee, Jackson C. Measures of rapid resolution of migraine symptoms and patient acceptance to treatment following eletriptan. sumatriptan and placebo [abstract]. Neurology 1998 Apr: 50 Suppl. 4: A375-376